DOP2022000152A - Vacunas de arn contra el coronavirus - Google Patents

Vacunas de arn contra el coronavirus

Info

Publication number
DOP2022000152A
DOP2022000152A DO2022000152A DO2022000152A DOP2022000152A DO P2022000152 A DOP2022000152 A DO P2022000152A DO 2022000152 A DO2022000152 A DO 2022000152A DO 2022000152 A DO2022000152 A DO 2022000152A DO P2022000152 A DOP2022000152 A DO P2022000152A
Authority
DO
Dominican Republic
Prior art keywords
vaccines against
rna vaccines
against coronavirus
vaccines
coronavirus
Prior art date
Application number
DO2022000152A
Other languages
English (en)
Inventor
Stewart-Jones Guillaume
Narayanan Elisabeth
Bennett Hamilton
Carfi Andrea
Metkar Mihir
Presnyak Vladimir
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of DOP2022000152A publication Critical patent/DOP2022000152A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción se refiere a vacunas de ácido ribonucleico (ARN) contra el coronavirus, así como a métodos de uso de las vacunas y composiciones que comprenden las vacunas.
DO2022000152A 2020-01-28 2022-07-26 Vacunas de arn contra el coronavirus DOP2022000152A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062967006P 2020-01-28 2020-01-28
US202062971825P 2020-02-07 2020-02-07
US202063002094P 2020-03-30 2020-03-30
US202063009005P 2020-04-13 2020-04-13
US202063016175P 2020-04-27 2020-04-27
PCT/US2021/015145 WO2021154763A1 (en) 2020-01-28 2021-01-26 Coronavirus rna vaccines

Publications (1)

Publication Number Publication Date
DOP2022000152A true DOP2022000152A (es) 2022-10-31

Family

ID=74669543

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000152A DOP2022000152A (es) 2020-01-28 2022-07-26 Vacunas de arn contra el coronavirus

Country Status (15)

Country Link
US (1) US20230108894A1 (es)
EP (1) EP4096710A1 (es)
JP (1) JP2023511633A (es)
KR (1) KR20220133224A (es)
CN (1) CN115175698A (es)
AU (1) AU2021213108A1 (es)
BR (1) BR112022014837A2 (es)
CA (1) CA3168902A1 (es)
CO (1) CO2022011685A2 (es)
DO (1) DOP2022000152A (es)
IL (1) IL295016A (es)
MX (1) MX2022009280A (es)
PE (1) PE20221756A1 (es)
TW (1) TW202142556A (es)
WO (1) WO2021154763A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021156267A1 (en) 2020-02-04 2021-08-12 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
CN113521268A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
WO2021159130A2 (en) * 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
WO2022218503A1 (en) * 2021-04-12 2022-10-20 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
WO2022101470A1 (en) * 2020-11-16 2022-05-19 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
CN112575008B (zh) * 2020-12-31 2023-03-24 四川大学华西医院 编码新型冠状病毒的结构蛋白的核酸分子以及新型冠状病毒疫苗
JP2024503698A (ja) * 2021-01-15 2024-01-26 モデルナティエックス インコーポレイテッド 変異型株ベースのコロナウイルスワクチン
EP4277653A1 (en) * 2021-01-15 2023-11-22 ModernaTX, Inc. Variant strain-based coronavirus vaccines
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
WO2022215036A1 (en) * 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
AU2022271249A1 (en) 2021-05-04 2023-11-16 BioNTech SE Immunogen selection
CN115594742A (zh) * 2021-07-09 2023-01-13 复旦大学（Cn） 一种冠状病毒s蛋白变体及其应用
CA3235867A1 (en) 2021-10-22 2023-04-27 Munir MOSAHEB Mrna vaccine composition
WO2023086961A1 (en) 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023096858A1 (en) 2021-11-23 2023-06-01 Senda Biosciences, Inc. A bacteria-derived lipid composition and use thereof
TW202332685A (zh) * 2021-11-30 2023-08-16 美商諾瓦瓦克斯股份有限公司 冠狀病毒疫苗配製品
CN117580587A (zh) * 2021-12-03 2024-02-20 苏州艾博生物科技有限公司 基于源自SARS-CoV-2奥密克戎毒株的序列的冠状病毒核酸疫苗
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
KR20230095025A (ko) * 2021-12-20 2023-06-28 아이진 주식회사 변이 SARS-CoV-2 백신 조성물 및 이의 용도
WO2023121131A1 (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 코로나바이러스 백신
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2023154818A1 (en) * 2022-02-09 2023-08-17 Modernatx, Inc. Mucosal administration methods and formulations
CN114404584B (zh) * 2022-04-01 2022-07-26 康希诺生物股份公司 一种新型冠状病毒mRNA疫苗及其制备方法和用途
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
TW202406929A (zh) 2022-05-05 2024-02-16 比利時商ｅＴｈｅＲＮＡ免疫治療公司 多表位構築體
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
JP5514727B2 (ja) 2007-09-26 2014-06-04 イントレキソン コーポレーション 合成５’ｕｔｒ、発現ベクター、および導入遺伝子の発現を増加させる方法
CN103911378A (zh) 2007-12-11 2014-07-09 斯克利普斯研究所 涉及mRNA翻译增强因子的组合物和方法
AU2010278309B2 (en) 2009-07-31 2013-10-31 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
AU2012267531B2 (en) 2011-06-08 2017-06-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
CN105209490A (zh) 2013-03-14 2015-12-30 夏尔人类遗传性治疗公司 用于递送mrna编码的抗体的方法和组合物
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
ES2795249T3 (es) 2013-03-15 2020-11-23 Translate Bio Inc Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas
JP6648019B2 (ja) 2013-08-21 2020-02-14 キュアバック アーゲー Ｒｎａコードされたタンパク質の発現を促進するための医薬的組成物、医薬的組成物の製造のための修飾ｒｎａの使用、および、医薬的組成物を含むパーツキット
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
RU2717986C2 (ru) 2013-12-30 2020-03-27 Куревак Аг Искусственные молекулы нуклеиновой кислоты
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
KR101793271B1 (ko) 2015-07-09 2017-11-20 인텔렉추얼디스커버리 주식회사 공기압을 이용한 휴대용 살균수 스프레이건
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3558356A2 (en) * 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
MA49913A (fr) 2017-08-18 2021-05-05 Modernatx Inc Variants d'arn polymérase

Also Published As

Publication number Publication date
EP4096710A1 (en) 2022-12-07
WO2021154763A1 (en) 2021-08-05
JP2023511633A (ja) 2023-03-20
MX2022009280A (es) 2022-08-16
AU2021213108A1 (en) 2022-08-18
CO2022011685A2 (es) 2022-08-30
US20230108894A1 (en) 2023-04-06
PE20221756A1 (es) 2022-11-11
CA3168902A1 (en) 2021-08-05
TW202142556A (zh) 2021-11-16
KR20220133224A (ko) 2022-10-04
BR112022014837A2 (pt) 2022-09-27
CN115175698A (zh) 2022-10-11
IL295016A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
DOP2022000152A (es) Vacunas de arn contra el coronavirus
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
CL2018001053A1 (es) Vacuna contra el virus sincicial respiratorio
BR112018008078A2 (pt) vacina de vírus influenza de amplo espectro
CL2018001056A1 (es) Vacuna contra el virus herpes simplex
BR112022015565A2 (pt) Vacinas de domínio de mrna para sars-cov-2
BR112022015053A2 (pt) Composições imunizantes contra vírus respiratórios
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
AR050972A1 (es) Microarn
CO2022009538A2 (es) Arn guía antisentido con región funcional añadida para editar arn blanco
AR069883A1 (es) Virus de la estomatitis vesicular geneticamente modificado, composicion inmunogenica que lo comprende, metodo para producirlo, metodos para adaptar un virus para crecer en el cultivo de cedula y para proteger un mamifero contra la infeccion con un organismo patogeno
WO2023283642A8 (en) Pan-human coronavirus concatemeric vaccines
UY37179A (es) Composiciones producidas por microorganismos con actividad estimuladora sobre las plantas
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
AR050211A1 (es) Composiciones y metodos que usan interferencia de arn para el control de nematodos
BR112015000520A2 (pt) agente de espessamento estável com lipase
AR065100A1 (es) Plantas con rasgos relacionados con el rendimiento mejorado y un metodo para producirlas
CL2021000005A1 (es) Tiofencarboxamidas sustituidas y análogos de las mismas
PE20121258A1 (es) Agente y metodo de control para podredumbre blanda
CL2011000583A1 (es) Composicion plaguicida que comprende un derivado del ácido alfa-alcoxifenil-acetico y un compuesto neonicotenoide.
CO2023015036A2 (es) Composición inmunogénica contra la influenza
AR121205A1 (es) Vacunas de arn contra el coronavirus
AR069224A1 (es) Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
CL2011001097A1 (es) Composicion de vacuna que comprende e. meleagrimitis 2 y meleagrimitis 1; uso de dicha vacuna para inmunizar un pavo contra la cocciodiosis; metodo para identificar un aislado de eimeria como una eimeria meleagrimitis 2; y kit de amplificacion por pcr.